Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Age and Insulin Resistance (AGIR)

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2016 by University of Lausanne
Centre Hospitalier Universitaire Vaudois
Information provided by (Responsible Party):
Francesca Amati, University of Lausanne Identifier:
First received: October 14, 2010
Last updated: October 24, 2016
Last verified: October 2016

Insulin resistance is a crucial factor for the development of type 2 diabetes and a major health problem for older adults. It is the principal mechanism by which obesity is considered to increase the risk for type 2 diabetes and is a key feature of the metabolic syndrome. The elevated prevalence of obesity and type 2 diabetes in the older population has important consequences on the morbidity and mortality as well as on the economic burden on society. Controversy currently exists as to whether or not aging contributes to insulin resistance. Many potential factors confound the association between aging and insulin resistance, including obesity and physical inactivity.

Ectopic lipid depositions, defined as an excess accumulation of triglycerides in non adipose tissues such as in the liver (intrahepatic lipids) and within the muscle fibers (intramyocellular lipids), are positively associated with obesity and insulin resistance. Furthermore, the accumulation of intracellular lipids is often cited as being a key determinant in the underlying mechanisms of insulin resistance. In addition of playing an important role in obesity and type 2 diabetes, these ectopic fat depositions are also observed in common conditions such as aging and physical inactivity.

The intervention trial will test in skeletal muscle, liver and heart of sedentary obese volunteers, normal weight volunteers and masters athletes, the overall hypotheses that exercise improvement of fat oxidation capacity and/or decrease of damaging fat metabolites is a primary factor that predicts the improvement in insulin resistance.

Condition Intervention
Physical Inactivity
Behavioral: Physical activity

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: In French AGIR Means to Get Into Action. This is the Generic Title of Our Study.

Resource links provided by NLM:

Further study details as provided by University of Lausanne:

Primary Outcome Measures:
  • Insulin sensitivity [ Time Frame: 0-4 months ]
  • Ectopic lipids [ Time Frame: 0-4 months ]
  • Oxidative capacity [ Time Frame: 0-4 months ]

Secondary Outcome Measures:
  • Body composition [ Time Frame: 0-4 months ]
  • Metabolic flexibility [ Time Frame: 0-4 months ]
  • Exercise efficiency [ Time Frame: 0-4 months ]
  • Physical fitness [ Time Frame: 0-4 months ]

Estimated Enrollment: 150
Study Start Date: October 2010
Estimated Study Completion Date: October 2019
Estimated Primary Completion Date: October 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Sedentary obese Behavioral: Physical activity
Supervised exercise intervention
Experimental: Sedentary normal weight Behavioral: Physical activity
Supervised exercise intervention
No Intervention: Athletes


Ages Eligible for Study:   60 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Age 60-80
  • Sedentary or highly trained
  • BMI 18-40
  • Non-Smoker
  • Normal glucose tolerance or impaired glucose tolerance
  • Willingness to comply with the protocol

Exclusion Criteria:

  • Contraindication to moderate exercise or clinical conditions precluding from joining an exercise program, such as clinically significant cardiovascular disease, peripheral vascular disease, uncontrolled hypertension, neurological or orthopedic disease
  • Recent weight loss or weight gain
  • Known diabetes
  • Known drugs to affect glucose homeostasis such as nicotinic acid, glucocorticoids
  • Severe anemia or lipid disturbances, hepatic or renal disease
  • Recent history of cancer
  • Hypothyroidism
  • Recent hormone replacement therapy
  • Known allergy to lidocaine or other local anesthetic
  • Positive stress test
  • Active alcohol or substance abuse
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01224886

Contact: Francesca Amati, MD, PhD +41 21 692 5552

University of Bern Active, not recruiting
Bern, Switzerland
UNIL and CHUV Recruiting
Lausanne, Switzerland, 1005
Contact: Francesca Amati, MD, PhD    +41 21 692 5552   
Principal Investigator: Francesca Amati, MD, PhD         
Sub-Investigator: Luc Tappy, MD         
Sponsors and Collaborators
University of Lausanne
Centre Hospitalier Universitaire Vaudois
Principal Investigator: Francesca Amati, MD,PhD University of Lausanne
  More Information

Responsible Party: Francesca Amati, Associate Professor, University of Lausanne Identifier: NCT01224886     History of Changes
Other Study ID Numbers: AGIR
Protocol 188/10 ( Other Identifier: Ethics committee )
Study First Received: October 14, 2010
Last Updated: October 24, 2016
Individual Participant Data  
Plan to Share IPD: Undecided

Keywords provided by University of Lausanne:
Insulin resistance
Ectopic lipids
Physical activity
Oxidative capacity
Metabolic syndrome

Additional relevant MeSH terms:
Insulin Resistance
Glucose Metabolism Disorders
Metabolic Diseases processed this record on April 26, 2017